Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies.
Featured
Latest Company Reports
- HIMSHims & Hers Health Inc Ordinary Shares - Class A
Hims Sees Margin Compression From Mix Shift and New Markets As Long-Term Targets Appear Lofty
- Rating
- Price
- $19.13
- Fair Value
- c>
- Uncertainty
- LOCK|fj ?t<c&
- Economic Moat
- LOCK|pMy
- Capital Allocation
- LOCK|DZMCR#
- DVADaVita Inc
DaVita Continues To Outperform Dialysis Peer Fresenius Medical Care
- Rating
- Price
- $179.28
- Fair Value
- LOCK|V#
- Uncertainty
- LOCK|<NY
- Economic Moat
- LOCK|v^mC
- Capital Allocation
- LOCK|!&!>$My
- FMSFresenius Medical Care AG ADR
Fresenius Medical Care Faces Near-Term Uncertainty, but We Still Expect Long-Term Improvement
- Rating
- Price
- $22.74
- Fair Value
- &cB
- Uncertainty
- LOCK|WW
- Economic Moat
- LOCK|<ty%
- Capital Allocation
- LOCK|slsvH<>
- IONSIonis Pharmaceuticals Inc
Narrow-Moat Ionis' Near-Term Tryngolza Launch Challenges Obscure Long-Term Earnings Power
- Rating
- Price
- $28.42
- Fair Value
- wJ
- Uncertainty
- LOCK|Xry
- Economic Moat
- LOCK|>QFQ
- Capital Allocation
- LOCK|C^!K#$&
- SOLVSolventum Corp
Solventum Is Strongly Focused on Remodeling Its Business
- Rating
- Price
- $90.08
- Fair Value
- N?
- Uncertainty
- LOCK|>fVt
- Economic Moat
- LOCK|&h
- Capital Allocation
- LOCK|@RvrjfV
- ONCBeOne Medicines Ltd ADR
BeOne's Brukinsa Remains Best-In-Class Drug for Chronic Lymphocytic Leukemia
- Rating
- Price
- $424.00
- Fair Value
- p<p
- Uncertainty
- LOCK|gv Y!TT
- Economic Moat
- LOCK|<C
- Capital Allocation
- LOCK|?j%>&!
- MRNAModerna Inc
Moderna's Impressive Intismeran Data in Melanoma Could Form Foundation of Oncology Portfolio
- Rating
- Price
- $250.83
- Fair Value
- LOCK|gX
- Uncertainty
- LOCK|@F cq?lh
- Economic Moat
- LOCK|CpW
- Capital Allocation
- LOCK|>PT@$%
- GMEDGlobus Medical Inc Class A
Favorable Market Position and Emerging Surgical Technologies Underscore Globus Medical’s Narrow Moat
- Rating
- Price
- $75.23
- Fair Value
- Y>@
- Uncertainty
- LOCK|Fsv
- Economic Moat
- LOCK|$%?c
- Capital Allocation
- LOCK|^!>G&&
- ZTSZoetis Inc Class A
Zoetis Demonstrates Credible Efforts To Play Defense in Face of Heightened Competition
- Rating
- Price
- $82.46
- Fair Value
- ^Ld
- Uncertainty
- LOCK|?$
- Economic Moat
- LOCK|k#?
- Capital Allocation
- LOCK|#QzdsLT
- XRAYDentsply Sirona Inc
Market Challenges and Margin Pressure Weigh on Dentsply's Near-Term Results
- Rating
- Price
- $9.68
- Fair Value
- LOCK|.^@
- Uncertainty
- LOCK|w? H@H<S
- Economic Moat
- LOCK|Y&
- Capital Allocation
- LOCK|kp&?^xw
- INCYIncyte Corp
No-Moat Incyte's Pipeline Momentum Strengthens Long-Term Growth Prospects
- Rating
- Price
- $120.29
- Fair Value
- RF%
- Uncertainty
- LOCK|@LfkC
- Economic Moat
- LOCK|K$^
- Capital Allocation
- LOCK|n<sjp>>
- GMABGenmab AS
Darzalex Continues to Support Growth as Narrow-Moat Genmab's Pipeline Advances
- Rating
- Price
- DKK 3,581.00
- Fair Value
- LOCK|$%L
- Uncertainty
- LOCK|#^M#
- Economic Moat
- LOCK|Y$$P
- Capital Allocation
- LOCK|Nck&&VR
- VTRSViatris Inc
Viatris Looks to New Launches, Pipeline Progression, and Cost Savings for Long-Term Growth
- Rating
- Price
- $20.86
- Fair Value
- ^?
- Uncertainty
- LOCK|$>g
- Economic Moat
- LOCK|^%
- Capital Allocation
- LOCK|FBhHCN
- CAHCardinal Health Inc
Cardinal Kicks Off 2027 With Margin Expansion and Accelerating Specialty Business
- Rating
- Price
- $276.79
- Fair Value
- #nr
- Uncertainty
- LOCK|<!t?c
- Economic Moat
- LOCK|Swfv&
- Capital Allocation
- LOCK|z^%P%^
- MCKMcKesson Corp
McKesson's Impressive Growth Momentum Fueled by Core Business Strength and Specialty Investments
- Rating
- Price
- $1,082.59
- Fair Value
- RNX
- Uncertainty
- LOCK|<ypQ
- Economic Moat
- LOCK|&&$B
- Capital Allocation
- LOCK|WVm&$%m
Largest Stocks in the Healthcare Sector
1-Day Chart | Name | Industry | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | Drug Manufacturers - General | LOCK|<xK@^&zl | LOCK|^@? | $1T | |||
| Johnson & Johnson JNJ | Drug Manufacturers - General | LOCK|!VG%L&k | LOCK|!^ | $676B | |||
| AbbVie Inc ABBV | Drug Manufacturers - General | LOCK|<l?^XH | LOCK|nzG | $519B | |||
| Merck & Co Inc MRK | Drug Manufacturers - General | LOCK|kt^v&< | LOCK|XQ& | $365B | |||
| UnitedHealth Group Inc UNH | Healthcare Plans | LOCK|t%pyw& | LOCK|R@^t> | $363B | |||
| Novartis AG ADR NVS | Drug Manufacturers - General | LOCK|wB%%w<m | LOCK|<t | $310B | |||
| AstraZeneca PLC AZN | Drug Manufacturers - General | LOCK|xhQMBFnM | LOCK|vb | $289B | |||
| Thermo Fisher Scientific Inc TMO | Diagnostics & Research | LOCK|?LH^^lbM | LOCK|gGR | $266B | |||
| Amgen Inc AMGN | Drug Manufacturers - General | LOCK|<%c&<>yY | LOCK|>l | $252B | |||
| Gilead Sciences Inc GILD | Drug Manufacturers - General | LOCK|F^^y!$& | LOCK|lS | $212B |
More in Healthcare
Eli Lilly Earnings: Medicare Zepbound Demand Outpaced Our Expectations, but Shares Overvalued
We think market prices have risen above Lilly’s fundamental value.
How Will the Midterm Elections Affect the US Economy?
Plus, why voters’ decisions could have more impact at the individual level.
Weekly Market Update: Stocks Flat as Energy Rises, Communication Services Fall
Zscaler and Qualys were among the week’s best performers.
Eli Lilly Stock Is Up 18% This Year. Is It Still a Buy Ahead of Earnings?
With weight-loss drugs driving growth, here’s what we’ll be looking for.
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism.
Johnson & Johnson Earnings: Pharma Momentum, but MedTech Headwinds Dampen Growth
We think the market continues to overvalue J&J stock.
UnitedHealth Earnings: Margin Improvement Continues in Risk-Taking Operations
We are boosting our near-term expectations on strong trends.
Stock Sector Outlooks: Morningstar’s Top Q4 Picks Across the Market
Morningstar analysts provide their sector outlooks and views on the best stocks to buy.
Healthcare: Stocks Had a Great Q3, as Defensive Nature and Steady Innovation Drew Interest
Medline and BioMarin are among our top stocks in the sector.
33 Undervalued Stocks to Buy Before the Market Shifts Again
Here’s the new list of Morningstar’s top analyst picks for the fourth quarter of 2026.
United States